Study #2017-1067
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Glesatinib, Nivolumab, Sitravatinib, Mocetinostat
Description
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Non-Small-Cell Lung
Study phase:
Phase II
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-767-1887
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.